Home Dialysis Plus, Ltd.
Home Dialysis Plus, Ltd. is listed today as Outset Medical, Inc.: market value, financials and filings are on its company page.
Funding rounds
6 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2025 | $4 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Jan 2020 | $115 M | No. 6 | $50 to $250 million | equity | SEC | |
| Aug 2018 | $132 M | No. 5 | $50 to $250 million | equity | SEC | |
| Jun 2017 | $4 M | No. 4 | $2 to $10 million | debt, options | SEC | |
| Apr 2017 | $76 M | No. 3 | $50 to $250 million | equity | SEC | |
| May 2015 | $60 M | No. 2 | $50 to $250 million | equity | SEC | |
| Feb 2010 | $10 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Outset Medical, Inc., its revenue in fiscal 2025 came from these product and service lines: Consumables Product $54.08 million (45%), Service and Other Revenue $34.67 million (29%), Consoles Product $30.73 million (26%).
Annual report (SEC XBRL) · Dec 2025
Home Dialysis Plus, Ltd. chose not to state its revenue in its newest notice of a funding round (Jan 2025).
SEC Form D · Jan 2025
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jan 2025
Products and services#
No products or services of Home Dialysis Plus, Ltd. are on record.
Investors#
11 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Warburg Pincus & Co | Other | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Warburg Pincus LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Warburg Pincus Partners GP LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Warburg Pincus Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Warburg Pincus Private Equity X, L.P. | Private equity | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Warburg Pincus X LLC | Other | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Warburg Pincus X, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Warburg Pincus X Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| WPP GP LLC | Other | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| WP X Finance, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| WPX GP, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 27 investors.
Largest shareholders today
Institutions holding Outset Medical, Inc. shares, as of Sep 30, 2026.
- FMR LLC$8 M14.50%
- BML Capital Management, LLC$8 M13.35%
- Perceptive Advisors LLC$2 M4.42%
- Vanguard Capital Management LLC$2 M4.13%
- Bank Of America Corp /de/$2 M3.54%
- PFM Health Sciences, LP$2 M3.08%
- Marshall Wace, LLP$1 M2.56%
- BlackRock, Inc.$1 M1.94%
- AQR Capital Management LLC$1 M1.82%
- Assenagon Asset Management S.A.$1 M1.80%
- Peapod Lane Capital LLC$1 M1.79%
- Geode Capital Management, LLC$1 M1.11%
- Clayton Partners LLC$1 M1.06%
- Acadian Asset Management LLC$1 M1.00%
- Morgan Stanley$0 M0.77%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| John T. Brottem | Executive officer | Jan 2025 |
| Marc T. Nash | Executive officer | Jan 2025 |
| Nabeel Ahmed | Executive officer | Jan 2025 |
| Leslie J. Trigg | Executive officer | Feb 2020 |
| Rebecca J. Chambers | Executive officer | Feb 2020 |
| Jeff Mack | Executive officer | Aug 2018 |
| Leslie Trigg | Executive officer | Aug 2018 |
| Joseph Rasmussen | Joseph Rasmussen is the Chief Financial Officer and Secretary of the Issuer. | Feb 2011 |
| Joseph J. Rasmussen | Joseph Rasmussen is the Chief Financial Officer and Secretary | Feb 2010 |
| Michael J. Baker | Michael J. Baker is the Chief Executive Officer | Feb 2010 |
| Andrea Saia | Director | Jan 2025 |
| Brent Lang | Director | Jan 2025 |
| Dale Jones | Director | Jan 2025 |
| Karen T. Drexler | Director | Jan 2025 |
| Keith Grossman | Director | Jan 2025 |
| Leslie Trigg | Director | Jan 2025 |
| Patrick T. Hackett | Director | Jan 2025 |
| Camilla Macapili Languille | Director | Feb 2020 |
| D. Keith Grossman | Director | Feb 2020 |
| Leslie J. Trigg | Director | Feb 2020 |
| Patrick Hackett | Director | Feb 2020 |
| Rohit Vishnoi | Director | Feb 2020 |
| Scott Bartos | Director | Feb 2020 |
| Thomas J. Carella | Director | Feb 2020 |
| Annette Rodriguez | Director | Aug 2018 |
| In Seon Hwang | Director | Aug 2018 |
| Tony Chou | Director | Jun 2017 |
| Bess Weatherman | Director | May 2015 |
| Noah Knauf | Director | May 2015 |
| Elizabeth H. Weatherman | Director | Feb 2011 |
| Michael Baker | Director | Feb 2011 |
| Sean Carney | Director | Feb 2011 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.